Recently, Guangzhou Junshi Biosciences Co., Ltd. officially submitted its listing application to the Hong Kong Stock Exchange (HKEX), aiming to list on the Main Board. This move marks a significant step toward capitalization for this innovative biotech company focused on solid tumor immunotherapies. Founded in 2017, Junshi Biosciences is led by a team of scientists and clinical experts with extensive experience in cancer immunotherapy. The company’s core technology centers on its proprietary Tumor-Infiltrating Lymphocyte (TIL) therapy, with multiple clinical trials underway in China for indications including melanoma, cervical cancer, and non-small cell lung cancer—showing promising results. According to its prospectus, the company intends to use the proceeds from the offering primarily to advance clinical development of its lead programs, expand manufacturing capacity, and strengthen its global intellectual property portfolio. In recent years, as Chinese biopharma firms accelerate their global expansion, the HKEX has become a preferred listing venue due to its accommodating policies for pre-revenue biotech companies. Junshi’s pursuit of a Hong Kong listing is expected not only to enhance its brand recognition and fundraising capabilities but also to provide fresh momentum to China’s cellular therapy sector.
近日，广州君赛生物科技有限公司正式向香港联合交易所（港交所）提交了上市申请书，拟在主板挂牌上市。此举标志着这家专注于实体瘤免疫细胞治疗的创新生物技术公司迈出了资本化的重要一步。君赛生物成立于2017年，核心团队由多位在肿瘤免疫治疗领域具有丰富经验的科学家和临床专家组成。公司以自主研发的TIL（肿瘤浸润淋巴细胞）疗法为核心，已在中国开展多项针对黑色素瘤、宫颈癌、非小细胞肺癌等适应症的临床试验，并取得积极进展。根据招股书披露，君赛生物计划将本次募集资金主要用于推进核心产品的临床开发、扩大生产能力和加强全球知识产权布局。近年来，随着中国创新药企加速国际化，港股市场因其对未盈利生物科技企业的包容性政策，成为众多Biotech公司的首选上市地。君赛生物此次冲刺港股，不仅有望提升其品牌影响力和融资能力，也将为中国细胞治疗领域的发展注入新动力。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/1501.html